ASCO 2023 | Phase II trial of retifanlimab and INCAGN01876 with FSRT in glioblastoma

Stephen Joseph Bagley, MD, MSCE, Hospital of the University of Pennsylvania, Philadelphia, PA, presents results from a Phase II trial (NCT04225039) of retifanlimab and INCAGN01876, a PD-1 inhibitor and GITR agonist respectively with fractionated stereotactic radiotherapy (FSRT) in patients with recurrent glioblastoma (rGBM). The progression-free survival (PFS) of patients who did not undergo surgery was not significantly improved, whereas PFS and overall survival was improved in patients who received FSRT in the non-surgical arm. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.